-

- - MERIBEL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-004463-41-ES

Enrollment

Registered

2013-02-04

Start date

2013-03-03

Completion date

Unknown

Last updated

2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Halaven Product Name: HALAVEN Product Code: - Pharmaceutical Form: Solution for injection INN or Proposed INN: ERIBULIN CAS Number: 253128-41-5 Concentration unit: mg/m2 milligram(s)/squar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 26 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 26

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Main Objective: -;Secondary Objective: -;Primary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Secondary

Measure	Time frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Countries

Portugal, Spain

Contacts

Public ContactMedica Scientia Innovation Research

Medica Scientia Innovation Research (MedSIR ARO)

joan.mercadal@medsir.org003469534 87 12

Outcome results